Profile of mRNA Expression of Ki-67 in Breast Cancer Patients Pre- and Post- Chemotherapy

Abstract

Abstract: Background: Proliferation is a distinct hallmarks of cancer. Ki-67 designated as a marker of proliferation in solid\ud tumors. The proliferative activity of tumor demonstrated by expression of Ki-67 in breast cancer has been associated with a\ud poor prognosis. Changes in the relative proportions of Ki-67 can be observed during chemotherapy and may correlated with\ud clinical response in breast cancer. Purpose: Evaluate changes in mRNA expression of proliferation marker Ki-67 in breast\ud cancer patients pre- and post-chemotherapy in relation with clinical response to chemotherapy. Method: This is a longitudinal\ud study, 30 subjects breast cancer tissue samples pre- and post-chemotherapy using cyclophosphamide, adriamycin, 5FU\ud regiment. We using qRT-PCR techniques to detect mRNA expression of Ki-67. Chemotherapy response is calculated using\ud RECIST criteria. Results: Mean value of Ki-67 mRNA expression on breast cancer patients pre-chemotheraphy was\ud 11.837??0.360. Mean value of Ki-67 mRNA expression on breast cancer patients post-chemotheraphy was 11.241??1.971. There\ud was no significant correlation between expression of Ki-67 mRNA prechemotherapy with clinical response to chemotherapy, p\ud = 0.862 (p ???0.05). There is a positive correlation between velocity of Ki-67 mRNA expression with clinical response with\ud value of r = 0.378, this correlation was significant with p = 0.020 (p<0.05). Conclusion: Chemotherapy cause decrease in\ud mRNA expression of Ki-67. There is insignificant correlation between expression of mRNA Ki-67 baseline with chemotherapy\ud response. Velocity of Ki-67 mRNA expression has significant correlation with clinical response to chemotherapy